A Phase 2, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 05 Oct 2023 Status changed from active, no longer recruiting to completed.
- 20 Jul 2023 Planned End Date changed from 18 Sep 2023 to 28 Sep 2023.
- 20 Jul 2023 Planned primary completion date changed from 17 Aug 2023 to 4 Aug 2023.